JPMorgan analyst Helen Zhu initiated coverage of Genscript Biotech with an Overweight rating and HK$30 price target. The company has a diversified business with accelerated growth in CAR-T, Zhu tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly